#1 Clinical Trials Search in Europe

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

3 1

What is this study about?

Sickle cell disease is a genetic blood condition that makes red blood cells stiff and shaped like a sickle, leading to painful episodes called VOC (blockages in small blood vessels). The study tests an oral medicine called etavopivat, which is provided in granule or tablet form, to see if it can reduce these painful episodes in children.

The purpose of the study is to determine whether etavopivat can lower the number of VOC events compared with placebo. Children are randomly assigned to receive either the study medicine or a matching placebo, and neither the participants nor the doctors know which one is being taken (double‑blind). The medication is taken by mouth each day for several months, with regular clinic visits for safety checks and blood tests that measure hemoglobin (the protein that carries oxygen), lactate dehydrogenase (an enzyme that rises when red cells break down), reticulocyte count (the number of young red cells), and bilirubin (a waste product from broken red cells). Information on hospital stays, emergency visits, and days missed from school is also collected, and at the end the frequency of painful episodes is compared between the two groups.

1 initial study visit

at the first visit, eligibility is confirmed and baseline information is collected. this includes a review of your medical history, blood tests, and questionnaires about your health and daily activities.

the purpose of these assessments is to establish a reference point for later comparison while you are participating in the study for sickle cell disease.

2 random assignment to treatment

after the baseline visit, you are randomly assigned to receive either the study drug etavopivat or a matching placebo. the study is double‑blind, so neither you nor the study staff know which one you receive.

3 starting the medication

you will begin taking an oral medication each day as instructed by the study team.

if you are assigned to the study drug, the form may be granules (etavopivat b 10041 or etavopivat b 10042) or a tablet (etavopivat c 10164). the label shows a dose of 00 mg, taken by mouth.

if you are assigned to the placebo, you will take a matching oral preparation that does not contain active medication.

4 regular study visits

you will attend scheduled visits throughout the trial. during each visit, blood samples are taken to check safety and effectiveness, and you complete questionnaires about pain, fatigue, and daily activities.

the study staff also ask about any episodes of vaso‑occlusive crisis (voc), which are painful events that can require medical attention.

5 ongoing monitoring of outcomes

throughout the trial, the number of voc events, hospital stays, emergency‑room visits, missed school days, and fatigue levels are recorded.

you will be asked to report any new symptoms, side effects, or changes in your health between visits.

6 completion of treatment period

after the predetermined treatment period ends, you stop taking the study medication.

a final set of assessments, including blood tests and questionnaires, is performed to evaluate the overall effect of the treatment.

7 final follow‑up visit

a follow‑up visit is scheduled after treatment ends to check for any delayed effects and to ensure safety.

the study team reviews all collected data and concludes your participation in the trial.

Who Can Join the Study?

  • Informed consent must be given before any study‑related activities are performed.
  • The child can be male or female.
  • The child must be between 2 and 11 years old at the time of randomisation.
  • The child must have a confirmed diagnosis of sickle cell disease (SCD) with documentation of the specific type (such as HbSS, HbSC, HbSβ0‑thalassaemia, HbSβ+ thalassemia, or other variants) from previous laboratory testing. Laboratory tests may include Hb electrophoresis, high‑performance liquid chromatography, or similar methods that examine the blood’s hemoglobin.
  • The child’s hemoglobin level must be at least 5.5 g/dL and no more than 10.5 g/dL at the screening visit. Hemoglobin is the protein in red blood cells that carries oxygen.
  • The child must have had at least 2 and no more than 15 documented vaso‑occlusive crises (VOC) in the 12 months before screening, with records in the medical chart. VOC are painful episodes caused by sickle cells blocking blood flow.
  • The child must meet any other requirements that are described in the study protocol.

Who Cannot Join the Study?

  • Allergic reaction (known or suspected) to the study drug or any similar medication.
  • Other reasons listed in the detailed study plan that may prevent participation.
  • Body weight less than 10 kilograms (about 22 pounds).
  • Any serious liver problem, such as:
    • Blood tests showing ALT or AST levels more than three times the normal range (these are enzymes that indicate liver injury).
    • Direct bilirubin level more than twice the normal range (bilirubin is a substance processed by the liver).
    • Diagnosed liver disease with scarring called cirrhosis or severe fibrosis.
  • Severe kidney problems, meaning an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m² (a measure of kidney function) or being on long‑term dialysis.
  • History of a clear stroke, bleeding inside the brain (intracranial haemorrhage), or serious blood‑vessel disease in the brain seen on a special scan called magnetic resonance angiography.
  • Iron deficiency (low blood iron or ferritin below 10 µg/L) if the person cannot take iron supplements during the study.
  • Deficiency of folate (vitamin B9) or vitamin B12 if the person cannot take the appropriate supplements during the study.
  • Inability or unwillingness to use malaria prevention methods (such as bed nets or recommended medicines) if living in an area where malaria is common.
  • Use of medicines that strongly increase the activity of liver enzymes called CYP3A4/5 within two weeks before starting the study or a need to use such medicines during the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hopital Necker Enfants Malades Paris France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Cgqqqt Hubxxfdcdmj Uqeofqnhgmhve Dn Dbyvv Dijon France
Aghxjzyit Uzr Amsterdam The Netherlands
Rqwqbz Dfvar Udyrwrtvgd Hptorcjq Paris France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
30.11.2026
The Netherlands The Netherlands
Not yet recruiting
30.11.2026

Trial locations

Investigated Drugs:

etavopivat (oral granules) is an investigational medicine being studied to help children with sickle cell disease. It is taken by mouth in a granule form that dissolves in the mouth or a drink. The drug works by improving how red blood cells produce and use energy, which can make them less likely to become stiff and stick together. By doing this, etavopivat may lower the number of painful episodes called vaso‑occlusive crises that children with sickle cell disease often experience.

etavopivat (tablet) is the same investigational medicine but provided as a tablet that is swallowed. Like the granule version, it is taken orally and aims to improve red blood cell energy metabolism. The goal is to reduce the frequency of painful vaso‑occlusive crises in children with sickle cell disease, helping them feel better and have fewer hospital visits.

Investigated Diseases:

Sickle cell disease – Sickle cell disease is a genetic condition that affects the blood’s red cells, causing them to become stiff and shaped like a crescent. These abnormal cells can block small blood vessels, leading to episodes of pain and reduced blood flow. Over time, the repeated blockages can cause damage to organs such as the spleen, kidneys, and bones. The disease often results in frequent pain crises, anemia, and increased need for medical care. Children may experience growth delays and fatigue as the condition progresses.

Trial ID:
2025-524464-38-00
Protocol code:
NN7535-8365
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Comparing morphine alone to morphine and lidocaine for pain relief in sickle cell anemia patients with vaso-occlusive crisis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium

  • A study testing gene therapy with Dream01 and imatinib for patients with severe sickle cell disease to improve red blood cell production

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France